Drug makers’ downsizing moves continue unabated in Japan. In the past three months alone, it was revealed that voluntary redundancy programs were being planned or launched for Pfizer, MSD, and Sanofi, affecting a total of over 600 staffers mainly in…
HOME > REGULATORY
REGULATORY
- Japan Industry Asks for AMED Funding of 50 Billion Yen to Build Big Data Platform
November 6, 2019
- Aso, CEFP Members Talked about Aducanumab at Oct. 28 Meeting, Minutes Reveal
November 6, 2019
- MOF Frets Financial Impact of Pricey Meds for Big Patient Populations, Cites Xolair’s Use in Pollen Allergy
November 5, 2019
- Australia Adds Japan to List of Countries Eligible for Expedited Review of New Drugs
November 5, 2019
- Key Japan Panel OKs Xolair as 1st Antibody Drug for Pollen Allergy
November 1, 2019
- MHLW Orders Label Revision for ADHD Treatment Concerta Based on New Distribution Control Policy
October 31, 2019
- Healthcare Providers Fret over Safety of Alternatives to Ranitidine amid Recalls
October 30, 2019
- PMDA Reviewing ILD Risks for Erleada, Xtandi
October 30, 2019
- MHLW Orders Label Revisions for Takecab to Include Pancytopenia to ADR List
October 30, 2019
- CEFP Members Prod Govt to Set Value-Based Target for Generic Promotion, but MHLW Wary
October 29, 2019
- Insurance Coverage of Cancer Genomic Profiling Tests in Early Stage Is Difficult: MHLW Official
October 29, 2019
- 1,419 ADR Victim Relief Claims Recieved in FY2018: MHLW
October 29, 2019
- 1st Topical JAK Inhibitor in Line for Japan Approval in January
October 28, 2019
- Decision on Whether Antibiotics Are Manufactured in Japan or Overseas Should be Left to Drug Makers: Govt
October 28, 2019
- Xolair Up for Review for Pollen Allergy, Taltz for Ankylosing Spondylitis on Oct. 31
October 25, 2019
- Kenporen Pushes for No Health Coverage or Higher Copay for OTC-Like Drugs
October 25, 2019
- Chuikyo Mixed on Integration of Kit Premium into Utility Premiums
October 24, 2019
- Chuikyo Payer Rep Moots Higher Prices for Biosames to Incentivize Biosimilar Development
October 24, 2019
- Chuikyo Snubs Industry Request to Revisit Comparator Criteria in New Drug Pricing
October 24, 2019
- Discussions on PMD Law Amendment Bill Start in Extraordinary Diet
October 24, 2019
ページ
As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In my home country of Australia, there is a famous candy called “Minties”. Minties has a long-running advertising campaign, presenting comical situations, with the caption, “It’s moments like these.” The phase has become part of the Aussie vernacular, meaning in…